Cancer diagnosis and therapy based on mutations in TGF-receptors

Simple item page
dc.contributorCase Western Reserve University, Cleveland (assignee)
dc.contributorMarkowitz, Sanford D.
dc.contributorBrattain, Michael G.
dc.contributorWillson, James K. V.
dc.contributorMedical College of Ohio, Toledo (assignee)
dc.date2001-09-18
dc.date.accessioned2024-05-25T13:20:38Z
dc.date.available2024-05-25T13:20:38Z
dc.descriptionThis invention is based on the discovery that the type II TGF~receptor (RII) is a cancer suppressor gene which is genetically inactivated (mutated) in approximately 25% of colon cancers, including nearly all colon cancers of the class identified as mutator/microsatellite instability/RER. Methods are provided for detecting inactivation of RII for use incancer diagnosis or prognosis.
dc.formatapplication/pdf
dc.identifierutoledo:1345
dc.identifieriid:utpatents-US6291237
dc.identifierPatent No.: US6291237
dc.identifierAppl. No.: 09/239864
dc.identifier.urihttps://hdl.handle.net/20.500.14324/6359
dc.language.isoeng
dc.publisherUnited States Patent and Trademark Office
dc.rightsNo Copyright - United States
dc.subject435/325
dc.subject435/419
dc.subject435/252.3
dc.subject435/254.11
dc.subject435/320.1
dc.subject536/23.5
dc.subject536/24.31
dc.titleCancer diagnosis and therapy based on mutations in TGF-receptors
dc.typeText
dc.typepatent

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
utoledo_1346.pdf
Size:
1.38 MB
Format:
Adobe Portable Document Format
Download

Collections

University of Toledo U.S. Patents